<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806208</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP046</org_study_id>
    <nct_id>NCT00806208</nct_id>
  </id_info>
  <brief_title>Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)</brief_title>
  <official_title>Phase I Evaluation of Safety, Pharmacokinetics and Activity of Escalating Dose Levels of MEDI 507 in Patients Receiving Methylprednisolone for Initial Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      A trial to assess safety of four doses of MEDI 507 combined with another drug for initial
      treatment of at least Grade II acute Graft-vs-Host Disease in recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess safety of four dose levels of MEDI 507
      combined with methylprednisolone for initial treatment of at least Grade II acute GvHD in
      stem cell or bone marrow allograft recipients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <completion_date type="Actual">March 2000</completion_date>
  <primary_completion_date type="Actual">January 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety; first infusion of study drug</measure>
    <time_frame>Through Study Day 44</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Graft-Versus-Host Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MEDI 507 and Methylprednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MEDI-507 and Methylprednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MEDI-507 and Methylprednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MEDI-507 and Methylprednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-507</intervention_name>
    <description>0.012 mg/kg MEDI 507 and Methylprednisolone</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-507</intervention_name>
    <description>0.04 mg/kg MEDI 507 and Methylprednisolone</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-507</intervention_name>
    <description>0.12 mg/kg MEDI 507 and Methylprednisolone</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-507</intervention_name>
    <description>0.4 mg/kg MEDI 507 and Methylprednisolone</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV (alternative) study days 0, 3,6, and 9</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. allogeneic bone marrow or hematopoietic stem cell graft recipients

          2. acute GvHD of at least Grade II severity

          3. receipt of at least 2 mg/kg of methylprednisolone (or equivalent corticosteroid)
             within eight to 24 hours prior to initial receipt of study drug

          4. evidence of engraftment (ANC over 1,000 cells/mm3)

          5. histologic evidence of GvHD from biopsy performed during the current episode

          6. receipt of GvHD prophylaxis of methotrexate, tacrolimus or cyclosporine

          7. age at least 18 years

          8. body weight under 130 kg

          9. Both males and females are eligible, but females of childbearing potential, unless
             previously surgically sterilized, agree to use an effective method of birth control
             (e.g., abstinence, intrauterine contraceptive device, oral contraceptives, diaphragm
             or condom in combination with contraceptive jelly, cream or foam, Norplant7 or
             DepoProvera7) beginning with the first study injection and continuing through 60 days
             after the final study injection.

        Exclusion Criteria:

          1. previous receipt of MEDI 507

          2. diagnosis of chronic GvHD

          3. previous treatment with any anti-T-cell monoclonal antibodies such as OKT73 or
             daclizumab (Zenapax7)

          4. receipt of antithymocyte globulin (ATGAM7 or other ATG) within 14 days

          5. treatment with more than 0.3 mg/kg/day of methylprednisolone (or equivalent
             corticosteroid) for more than 72 hours for the treatment of GvHD

          6. intolerance or history of intolerance to corticosteroids such that it is unlikely the
             patient will be able to complete at least ten days of corticosteroid therapy (2
             mg/kg/day of methylprednisolone or equivalent)

          7. more than one allogeneic bone marrow or hematopoietic stem cell allograft
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>J. Bruce McClain, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Institute of Transplant Sciences</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2008</study_first_submitted>
  <study_first_submitted_qc>December 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2008</study_first_posted>
  <last_update_submitted>December 10, 2008</last_update_submitted>
  <last_update_submitted_qc>December 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>J. Bruce McClain, M.D.</name_title>
    <organization>Medimmune Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

